// App-Quantinova.ai

: Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections

Researchers

Presenter

  • Anne O'Donnell

Principal Investigators

  • Juergen Froehlich

  • Bruce Thompson

  • Janice Dahms

  • David Cipolla

  • Angela Davis

  • Igor Gonda

  • Charles Haworth

Medical Centers

  • Georgetown University, Washington D.C., DC, United States

  • Aradigm Corp, Hayward, CA, United States,

  • Theta Hat Statistical Consultants LLC, Owings Mills, MD, United States.

  • NIH/NIEHS, Research Triangle Park, United States of America

  • Cambridge Centre for Lung Infection, Papworth Hospital, Cambridge, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Cystic Fibrosis

Biomarkers

  • N/A

Drug/Treatment

  • ARD-3150

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved